AbCellera Biologics Inc.ABCLNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -44.98% | -57.45% | +133.29% | +37.62% | +788.20% |
| Gross Profit Growth | -44.98% | -57.45% | +133.29% | +37.62% | +788.20% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.25% | +1.70% | +1.46% | +1.36% | +1.40% |
| Weighted Average Shares Diluted Growth | +1.25% | +1.70% | +1.46% | +1.36% | +1.40% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +43.10% | +84.10% | +126.53% | +152.01% | +66.50% |
| Inventory Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -8.57% | -8.13% | -0.74% | -2.64% | -0.26% |
| Book Value per Share Growth | -9.49% | -10.97% | -10.65% | -11.78% | +6.58% |
| Debt Growth | -15.53% | -7.83% | +97.19% | +99.19% | +119.11% |
| R&D Expense Growth | -5.24% | +8.17% | -4.19% | +34.32% | +8.72% |
| SG&A Expenses Growth | +0.47% | -7.96% | -5.75% | +12.01% | -10.15% |